Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial By admin / 11/04/2020
A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) By admin / 11/04/2020
Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies By admin / 11/04/2020
The Dual PI3Kδ/CK1ε Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects on CLL T Cells By admin / 07/08/2020
TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma By admin / 06/22/2020
Long term Results of a Phase I/ Ib Study of Ibrutinib in Combination with Umbralisib in Patients with Relapsed/Refractory CLL or MCL By admin / 06/12/2020
Safety and Activity of the Once Daily Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma By admin / 06/12/2020
Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study By admin / 05/29/2020
A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis By admin / 04/30/2020
Long-term Follow-up Results From the Phase 2 Multicenter Study of Ublituximab(UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Multiple Sclerosis (RMS) By admin / 02/27/2020
